Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
about
Current and future trials of targeted therapies in cutaneous melanomaEffects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cellsNatural borneol, a monoterpenoid compound, potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damageA melanoma molecular disease modelInduction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaVertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB.A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.Phosphatidylinositol-3-kinase as a therapeutic target in melanomaIGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusBRAF(E600) in benign and malignant human tumours.Molecular targets in melanoma: time for 'ethnic personalization'p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumorsUnderstanding signaling cascades in melanomaModeling Melanoma In Vitro and In Vivo.Integrating BRAF/MEK inhibitors into combination therapy for melanoma.Targeting the RAS pathway in melanoma.Gab2-mediated signaling promotes melanoma metastasis.Sorafenib in the treatment of advanced hepatocellular carcinomaBiology of human cutaneous melanomaTargeting the MAPK pathway in melanoma: why some approaches succeed and other fail.PI3Kinase signaling in glioblastoma.A new era: melanoma genetics and therapeutics.In vitro three-dimensional tumor microenvironment models for anticancer drug discovery.Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.Inosine strongly enhances proliferation of human C32 melanoma cells through PLC-PKC-MEK1/2-ERK1/2 and PI3K pathways.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines.Melanoma cell-derived factors stimulate hyaluronan synthesis in dermal fibroblasts by upregulating HAS2 through PDGFR-PI3K-AKT and p38 signaling.Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage.RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways.
P2860
Q27022355-0E7AE767-B762-4D26-B458-C0EB6D2FAA19Q27852994-6ECCF829-0A98-4022-948A-AA93CC7FB7BEQ28487936-D359B132-113E-449E-8CAB-4C8E197280A6Q28488280-0A4C88FA-EB52-4BA4-A604-CA0E14F864C5Q28741507-E7114650-7E8D-4AE6-BD41-186F9A32766CQ33480990-1A617D7C-C905-4896-8D0F-B24B98DE123BQ34154783-ADF73416-B78D-4856-A1C7-944D50992247Q34497045-6D3CAEF4-6EC8-4BC8-92AF-4422C53D9819Q34682072-2BCE71A2-3A56-4CEB-942C-672F0AE89B0BQ34917495-9D6D739D-298B-4FF9-892C-57DE749647BFQ35233178-833CB45B-9D3F-4121-9604-86C7D7D50E6EQ35606261-AB25B227-565D-477F-B2BD-9CB13350A634Q36105608-0E835CF8-E681-4F55-BBA8-3C9F4542094FQ36347314-A209B80C-2EAA-435E-89B7-7D64146388F6Q36560775-507850C6-207F-4BD0-ACF0-C1471F60B957Q36921234-C7298497-0BA3-4400-9100-ED04D1BEF4D8Q36927065-AA4D3D65-0DFC-4126-BF6F-97A683082659Q36944185-DF57E6A3-A4FF-4D51-8B0F-CC9794518C57Q37034487-6661B34A-A8BE-4284-9E98-A3515FE99718Q37069214-4FE50212-80E5-4D10-9CA0-850050E75942Q37135238-A9FABAD2-809E-481C-B61C-CB3E3DC28A31Q37137004-EEA80202-2372-49C1-8AB2-948310EB14EAQ37164581-C52389EB-96C5-4570-AC1D-0A2D67367867Q37243535-314D6639-83E5-4829-8926-7C1742A45AC9Q37307195-007256E1-3D51-4983-B398-F2BB6EF5903AQ37745182-D51BEFE4-3C54-4DDB-9521-766A3BA5971DQ37808385-5DF66A40-9B8D-4C8A-BBFB-480368107A56Q37815139-52010BF8-DD84-4114-9F66-0E0269041B08Q38088281-1C492888-37BD-408A-8884-10C29776D5DDQ38091649-45D2F446-3233-4EDD-9413-7067605363D7Q38127412-81E1A40A-D611-4D50-805C-2C9AB48D4B73Q38219616-AE287895-664D-4FA2-BC6D-7AA8E582656EQ38983353-DC751BEC-3B50-477A-AA55-02A52F709A69Q38987177-C877AC7A-72E8-41FE-99A1-D8DB7B46F8C4Q39107981-8CBF1906-A7D9-4C9A-8885-21064C482524Q39127177-DC8131E3-5037-4B27-91C1-441E1D85D13EQ39210673-BA8E4578-3E7F-400C-BB14-D19BA0444E46Q39309282-09CC2C68-4929-4AD0-A330-183CCE0B127DQ39342682-29DE5543-7232-45A5-AD48-90E15F185FF4Q39434384-8B92ED48-25A0-48AC-A005-8FBE0E7B279A
P2860
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combined targeting of MAPK and ...... rategy for melanoma treatment.
@en
type
label
Combined targeting of MAPK and ...... rategy for melanoma treatment.
@en
prefLabel
Combined targeting of MAPK and ...... rategy for melanoma treatment.
@en
P2093
P2860
P1476
Combined targeting of MAPK and ...... trategy for melanoma treatment
@en
P2093
Lasithiotakis K
Schittek B
P2860
P304
P356
10.1111/J.1365-2133.2007.07821.X
P407
P50
P577
2007-03-28T00:00:00Z